These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 19539742)

  • 21. Quantifying the pathophysiological timeline of Alzheimer's disease.
    Yang E; Farnum M; Lobanov V; Schultz T; Verbeeck R; Raghavan N; Samtani MN; Novak G; Narayan V; DiBernardo A;
    J Alzheimers Dis; 2011; 26(4):745-53. PubMed ID: 21694449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Added diagnostic value of CSF biomarkers in differential dementia diagnosis.
    Le Bastard N; Martin JJ; Vanmechelen E; Vanderstichele H; De Deyn PP; Engelborghs S
    Neurobiol Aging; 2010 Nov; 31(11):1867-76. PubMed ID: 19150153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
    Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
    Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal stability of CSF biomarkers in Alzheimer's disease.
    Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N
    Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
    Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
    Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
    Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
    Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biological markers for diagnosis of Alzheimer's disease].
    Takeda M; Tanaka T; Kudo T; Okochi M; Kamino A; Tagami S
    Seishin Shinkeigaku Zasshi; 2004; 106(12):1610-4. PubMed ID: 15770965
    [No Abstract]   [Full Text] [Related]  

  • 28. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEε4 genotype.
    Popp J; Lewczuk P; Frommann I; Kölsch H; Kornhuber J; Maier W; Jessen F
    J Alzheimers Dis; 2010; 22(2):459-68. PubMed ID: 21084733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
    Galasko D
    J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's biomarker initiative hits its stride.
    Miller G
    Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956
    [No Abstract]   [Full Text] [Related]  

  • 32. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
    Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sugar chains of cerebrospinal fluid transferrin as a new biological marker of Alzheimer's disease.
    Taniguchi M; Okayama Y; Hashimoto Y; Kitaura M; Jimbo D; Wakutani Y; Wada-Isoe K; Nakashima K; Akatsu H; Furukawa K; Arai H; Urakami K
    Dement Geriatr Cogn Disord; 2008; 26(2):117-22. PubMed ID: 18654083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.
    Brandt C; Bahl JC; Heegaard NH; Waldemar G; Johannsen P
    Dement Geriatr Cogn Disord; 2008; 25(6):553-8. PubMed ID: 18536519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden--regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
    Isaac M; Vamvakas S; Abadie E; Jonsson B; Gispen C; Pani L
    Eur Neuropsychopharmacol; 2011 Nov; 21(11):781-8. PubMed ID: 21903360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers of Alzheimer's disease: the present and the future.
    Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
    Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.
    Mattsson N; Andreasson U; Carrillo MC; Persson S; Shaw LM; Zegers I; Zetterberg H; Blennow K
    Biomark Med; 2012 Aug; 6(4):401-7. PubMed ID: 22917142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
    Kang JH; Korecka M; Figurski MJ; Toledo JB; Blennow K; Zetterberg H; Waligorska T; Brylska M; Fields L; Shah N; Soares H; Dean RA; Vanderstichele H; Petersen RC; Aisen PS; Saykin AJ; Weiner MW; Trojanowski JQ; Shaw LM;
    Alzheimers Dement; 2015 Jul; 11(7):772-91. PubMed ID: 26194312
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species.
    Dillen L; Cools W; Vereyken L; Timmerman P
    Bioanalysis; 2011 Jan; 3(1):45-55. PubMed ID: 21175366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.